- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02096653
Fluoroscopically-guided Versus Landmark-guided Sacroiliac Joint Injections
Randomized, Controlled, Double-blind, Comparative-effectiveness Study Comparing Fluoroscopically-guided and Landmark-guided Sacroiliac Joint Injections
In this study, the investigators are attempting to determine whether intra- or extra-articular injections are more effective; the relative prevalence rate of intra-articular and extra-articular SI joint pain; and the accuracy of extra-articular injections using fluoroscopy as the reference standard. 124 consecutive patients with mechanical low back pain below L5, tenderness overlying the SI joint(s) and at least 3 positive provocative maneuvers will be randomized to receive SI joint injections by 2 different approaches.
Group 1 will receive fluoroscopically-guided injections into the joint. Group 2 will receive landmark-guided injections into the tender area around the joint. In order to determine whether the injection in group 2 was intra-articular or extra-articular, an x-ray will be done after the injection to ascertain the location of contrast spread. The primary outcome measure will be pain relief at 1-month. Patients who obtain benefit at 1-month will be followed at 3-months, while those who fail to obtain benefit will exit the study to receive alternative care.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
California
-
San Diego, California, États-Unis
- Naval Hospital-San Diego
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21205
- Johns Hopkins Hospital
-
Rockville, Maryland, États-Unis, 20889
- Walter Reed National Military Medical Center
-
-
Pennsylvania
-
Hershey, Pennsylvania, États-Unis, 17033
- Penn State
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age > 18;
- Low back pain principally below the L5 vertebra;
- Three out of 6 positive SI joint provocative maneuvers;
- Agreed to undergo SI joint injection for diagnostic/ therapeutic purposes;
- Average pain score > 3/10 over the past week;
- Pain duration > 6 weeks;
Exclusion Criteria:
- Previous SI joint injection;
- Leg pain > back pain or lower leg pain > upper leg pain
- Active inflammatory spondyloarthropathy (e.g. ankylosing spondylitis);
- Untreated coagulopathy;
- Allergy to contrast dye or bupivacaine;
- Pain > 20 years in duration;
- Poorly controlled psychiatric (e.g. PTSD) or medical (congestive heart failure) condition
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: X-ray guided intra-articular injection
Injection of 40 mg depomethylprednisolone and 2 ml 0.5% bupivacaine into the SI (sacroiliac joint) cavity under fluoroscopic guidance
|
Injection of steroid and local anesthetic into the joint cavity using fluoroscopic guidance
|
|
Comparateur actif: Landmark-guided SI joint injection
Injection of 40 mg depomethylprednisolone and 2 ml 0.5% bupivacaine at the point of maximal tenderness (3 ml)
|
Injection of steroid into the joint area based on palpation.
The injection may be inside the joint (intra-articular) or outside the joint in the ligaments (extra-articular)
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Average Back Pain at 1 Month Measured Using the Numeric Pain Scale
Délai: 1 month from the start of treatment
|
This outcome measure compares the average back pain at baseline to the average back pain 1 month after the start of treatment.
This is measured using the Numeric Pain Scale.
The Numeric Pain Scale ranges from 0-10.
0 being no pain at all and 10 being the worst imaginable pain possible.
The group receiving fluoroscopically-guided intra-articular injection is compared to the group receiving landmark-guided injections.
|
1 month from the start of treatment
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Résultats liés à l'invalidité mesurés à 1 mois à l'aide de l'indice d'invalidité d'Oswestry
Délai: 1 mois après le début du traitement
|
Capacité fonctionnelle mesurée à l'aide de l'indice d'incapacité d'Oswestry.
La gamme de scores possibles pour l'indice d'invalidité d'Oswestry est de 0 à 100.
0 équivaut à aucune incapacité et 100 est l'incapacité maximale possible.
|
1 mois après le début du traitement
|
|
Résultats liés à l'invalidité mesurés à 3 mois à l'aide de l'indice d'invalidité d'Oswestry
Délai: 3 mois après le début du traitement
|
Capacité fonctionnelle mesurée à l'aide de l'indice d'incapacité d'Oswestry.
La gamme de scores possibles pour l'indice d'invalidité d'Oswestry est de 0 à 100.
0 équivaut à aucune incapacité et 100 est l'incapacité maximale possible.
|
3 mois après le début du traitement
|
|
Worst Back Pain at 1 Month Measured Using the Numeric Pain Scale
Délai: 1 month from the start of treatment
|
This outcome measure compares the worst back pain at baseline to the worst back pain at 1 months after the start of treatment.
This is measured using the Numeric Pain Scale.
The Numeric Pain Scale ranges from 0-10.
0 being no pain at all and 10 being the worst imaginable pain possible.
The group receiving fluoroscopically-guided intra-articular injection is compared to the group receiving landmark-guided injections.
|
1 month from the start of treatment
|
|
Average Back Pain at 3 Months Measured Using the Numeric Pain Scale
Délai: 3 months from the start of treatment
|
This outcome measure compares the average back pain at baseline to the average back pain at 3 months after the start of treatment.
This is measured using the Numeric Pain Scale.
The Numeric Pain Scale ranges from 0-10.
0 being no pain at all and 10 being the worst imaginable pain possible.
The group receiving fluoroscopically-guided intra-articular injection is compared to the group receiving landmark-guided injections.
|
3 months from the start of treatment
|
|
Worst Back Pain at 3 Months Measured Using the Numeric Pain Scale
Délai: 3 months after the start of treatment
|
This outcome measure compares the worst back pain at baseline to the worst back pain at 3 months after the start of treatment.
This is measured using the Numeric Pain Scale.
The Numeric Pain Scale ranges from 0-10.
0 being no pain at all and 10 being the worst imaginable pain possible.
The group receiving fluoroscopically-guided intra-articular injection is compared to the group receiving landmark-guided injections.
|
3 months after the start of treatment
|
|
Patient satisfaction of the procedure at 1 month measured using the Likert Scale
Délai: 1 month
|
Patient satisfaction is measured at 1 month after the procedure using the Likert Scale.
The range of possible scores for the Likert Scale are 1-5.
I being very unsatisfied and 5 being very satisfied.
|
1 month
|
|
Patient satisfaction of the procedure at 3 months measured using the Likert Scale
Délai: 3 months
|
Patient satisfaction is measured at 1 month after the procedure using the Likert Scale.
The range of possible scores for the Likert Scale are 1-5.
I being very unsatisfied and 5 being very satisfied.
|
3 months
|
|
Positive categorical outcome
Délai: 1 month
|
Decrease in average back pain score at 1 month of greater or equal to 2 points coupled with a satisfaction score > 3 on a 1-5 scale
|
1 month
|
|
Positive categorical outcome
Délai: 3 months
|
Decrease in average back pain score at 3 months of greater or equal to 2 points coupled with a satisfaction score > 3 on a 1-5 scale
|
3 months
|
|
Positive diagnostic blocks
Délai: 6 hours
|
The percentage of participants who experience greater or equal to 50% pain relief based on their pain diary
|
6 hours
|
Collaborateurs et enquêteurs
Publications et liens utiles
Publications générales
- Cohen SP, Chen Y, Neufeld NJ. Sacroiliac joint pain: a comprehensive review of epidemiology, diagnosis and treatment. Expert Rev Neurother. 2013 Jan;13(1):99-116. doi: 10.1586/ern.12.148.
- Cohen SP, Bicket MC, Kurihara C, Griffith SR, Fowler IM, Jacobs MB, Liu R, Anderson White M, Verdun AJ, Hari SB, Fisher RL, Pasquina PF, Vorobeychik Y. Fluoroscopically Guided vs Landmark-Guided Sacroiliac Joint Injections: A Randomized Controlled Study. Mayo Clin Proc. 2019 Apr;94(4):628-642. doi: 10.1016/j.mayocp.2018.08.038. Epub 2019 Mar 8.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- NA_00092414
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .